Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01ASJ
|
||||
| Former ID |
DIB008334
|
||||
| Drug Name |
Nalbuphine hydrochloride ER
|
||||
| Synonyms |
PW-4142; Nalbuphine hydrochloride ER (oral, pain, TIMERx); Nalbuphine (oral, extended release, Geminex), Penwest; Nalbuphine (oral, extended release, TIMERx), Penwest; Nalbuphine ER (oral, pain, Geminex), Penwest; Nalbuphine ER (oral, pain, TIMERx), Penwest; Nalbuphine hydrochloride (oral, extended release, TIMERx), Penwest; Nalbuphine hydrochloride ER (oral, pain, TIMERx), Penwest
|
||||
| Indication | Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89] | Phase 3 | [1] | ||
| Company |
Penwest Pharmaceuticals Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC<br />6CCC6)c45
|
||||
| InChI |
1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
|
||||
| InChIKey |
NETZHAKZCGBWSS-CEDHKZHLSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Modulator | ||
| Kappa-type opioid receptor | Target Info | Modulator | |||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addictionhsa04080:Neuroactive ligand-receptor interaction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin releaseP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Opioid prodynorphin pathway | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00323154) Nalbuphine for the Treatment of Opioid Induced Pruritus in Children. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.